Agilent is a world leader in nucleic acid synthesis and is extending our expertise into chemically synthesized long RNA. Using a patented, proprietary chemistry1, Agilent makes the synthesis of long RNA oligonucleotides as robust and efficient as DNA synthesis. Agilent uses this chemistry to synthesize and deliver high quality CRISPR guides, and our processing provides guides with few contaminants.
Agilent researchers have developed chemical modifications which improve the efficiency, stability, and specificity of guide RNAs in a variety of cell types. These modifications are patent pending and are available in a variety of options. 2,3
For Research Use Only. Not for use in diagnostic procedures.
(1) Douglas J. Dellinger, Zoltán Timár, Joel Myerson, Agnieszka B. Sierzchala,John Turner, Fernando Ferreira, Zoltán Kupihár, Geraldine Dellinger,Kenneth W. Hill, James A. Powell, Jeffrey R. Sampson, and Marvin H. Caruthers. Streamlined Process for the Chemical Synthesis of RNA Using 2'-O-Thionocarbamate-Protected Nucleoside Phosphoramidites in the Solid Phase, J. Am. Chem. Soc. 133, 11540–11556 (2011). DOI: 10.1021/ja201561z
(2) Ayal Hendel, Rasmus O Bak, Joseph T Clark, Andrew B Kennedy, Daniel E Ryan, Subhadeep Roy, Israel Steinfeld, Benjamin D Lunstad, Robert J Kaiser, Alec B Wilkens, Rosa Bacchetta, Anya Tsalenko, Douglas Dellinger, Laurakay Bruhn & Matthew H Porteus. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nature Biotechnology, Vol. 33 No. 9 (2015); doi:10.1038/nbt.3290
(3) (3) Daniel E. Ryan, David Taussig, Israel Steinfeld, Smruti M. Phadnis, Benjamin D. Lunstad, Madhurima Singh, Xuan Vuong, Kenji D. Okochi, Ryan McCaffrey, Magdalena Olesiak, Subhadeep Roy, Chong Wing Yung, Bo Curry, Jeffrey R. Sampson, Laurakay Bruhn, and Douglas J. Dellinger. Improving CRISPR–Cas specificity with chemical modifications in single-guide RNAs. Nucleic Acids Research, Vol. 46, No. 2 (2018); doi: 10.1093/nar/gkx1199
Patent Information: US 9,067,961, US 9,273,086, US 9,896,472